Therefore, much pharmaceutical research is aimed at designing drugs that bind to only their target proteins (Negative Design) with high affinity (typically 0.1-10 nM) or at improving the affinity between a particular drug and its in-vivo protein target (Positive Design).
Zbog toga je znatan deo farmaceutskih istraživanja usmeren na dizajn lekova koji se vezuju samo za njihove ciljane proteine s visokim afinitetom (tipično 0.1-10 nM) ili ka poboljšanju afiniteta pojedinog leka i njegovog in-vivo proteinskog cilja.